Association of Promoter Methylation of VGF and PGP9.5 with Ovarian Cancer Progression

PLoS ONE

Volumn 8, Issue 9, 2013, Pages

  Brait, Mariana ^a,b   Maldonado, Leonel ^a   Noordhuis, Maartje ^a,c   Begum, Shahnaz ^d   Loyo, Myriam ^a   Poeta, Maria Luana ^e   Barbosa, Alvaro ^f   Fazio, Vito M ^g   Angioli, Roberto ^g   Rabitti, Carla ^g   Marchionni, Luigi ^a   de Graeff, Pauline ^c   van der Zee, Ate G J ^c   Wisman, G Bea A ^c   Sidransky, David ^a   Hoque, Mohammad O ^a  

^a JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b INSTITUTO NACIONAL DE CÂNCER   (Brazil)

^c UNIVERSITY MEDICAL CENTER GRONINGEN   (Netherlands)

^d DEPARTMENT OF PATHOLOGY   (United States)

^e UNIVERSITY OF BARI   (Italy)

^f Hospital San Jose Tec de Monterrey   (Mexico)

^g UNIVERSITY CAMPUS BIO MEDICO   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

ADULT; AGED; ARTICLE; CANCER CELL CULTURE; CANCER GRADING; CANCER GROWTH; CANCER SPECIFIC SURVIVAL; CANCER STAGING; CANCER SURVIVAL; CELL GROWTH; CLINICAL FEATURE; CONTROLLED STUDY; DNA METHYLATION; FEMALE; GENE FREQUENCY; GENE OVEREXPRESSION; GENETIC ASSOCIATION; HUMAN; HUMAN CELL; IN VITRO STUDY; MAJOR CLINICAL STUDY; OVARY CANCER; OVERALL SURVIVAL; PGP9 5 GENE; POLYMERASE CHAIN REACTION; PROMOTER REGION; SURVIVAL RATE; SURVIVAL TIME; VGF GENE;

ADULT; AGED; AZACITIDINE; BASE SEQUENCE; COHORT STUDIES; DISEASE PROGRESSION; DNA METHYLATION; DNA PRIMERS; FEMALE; HUMANS; MIDDLE AGED; NERVE GROWTH FACTORS; OVARIAN NEOPLASMS; PROMOTER REGIONS, GENETIC; REAL-TIME POLYMERASE CHAIN REACTION; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; UBIQUITIN THIOLESTERASE;

EID: 84884691003     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0070878     Document Type: Article

References (53)

1. Jemal A, Bray F, (2011) Center MM, Ferlay J, Ward E, et al (2011) Global cancer statistics. CA Cancer J Clin 61: 69-90.
2. Siegel R, Naishadham D, Jemal A, (2013) Cancer statistics, 2013. CA Cancer J Clin 63: 11-30.
3. Cannistra SA, (2004) Cancer of the ovary. N Engl J Med 351: 2519-2529.
4. Ibanez de Caceres I, Battagli C, Esteller M, Herman JG, Dulaimi E, et al. (2004) Tumor cell-specific BRCA1 and RASSF1A hypermethylation in serum, plasma, and peritoneal fluid from ovarian cancer patients. Cancer Res 64: 6476-6481.
5. Holloway RW, Mehta RS, Finkler NJ, Li KT, McLaren CE, et al. (2002) Association between in vitro platinum resistance in the EDR assay and clinical outcomes for ovarian cancer patients. Gynecol Oncol 87: 8-16.
6. Wolffe AP, Matzke MA, (1999) Epigenetics: regulation through repression. Science 286: 481-486.
7. Jones PA, Baylin SB, (2002) The fundamental role of epigenetic events in cancer. Nat Rev Genet 3: 415-428.
8. Herman JG, Baylin SB, (2003) Gene silencing in cancer in association with promoter hypermethylation. N Engl J Med 349: 2042-2054.
9. Esteller M, (2007) Cancer epigenomics: DNA methylomes and histone-modification maps. Nat Rev Genet 8: 286-298.
10. Bird AP, (1986) CpG-rich islands and the function of DNA methylation. Nature 321: 209-213.
11. Feinberg AP, Vogelstein B, (1983) Hypomethylation distinguishes genes of some human cancers from their normal counterparts. Nature 301: 89-92.
12. Hoque MO, Begum S, Brait M, Jeronimo C, Zahurak M, et al. (2008) Tissue inhibitor of metalloproteinases-3 promoter methylation is an independent prognostic factor for bladder cancer. J Urol 179: 743-747.
13. Chang X, Monitto CL, Demokan S, Kim MS, Chang SS, et al. (2010) Identification of hypermethylated genes associated with cisplatin resistance in human cancers. Cancer Res 70: 2870-2879.
14. Anonymous (1971) Classification and staging of malignant tumours in the female pelvis. Acta Obstet Gynecol Scand 50: 1-7.
15. Hoque MO, Topaloglu O, Begum S, Henrique R, Rosenbaum E, et al. (2005) Quantitative methylation-specific polymerase chain reaction gene patterns in urine sediment distinguish prostate cancer patients from control subjects. J Clin Oncol 23: 6569-6575.
16. van Dongen JJ, Langerak AW, Bruggemann M, Evans PA, Hummel M, et al. (2003) Design and standardization of PCR primers and protocols for detection of clonal immunoglobulin and T-cell receptor gene recombinations in suspect lymphoproliferations: report of the BIOMED-2 Concerted Action BMH4-CT98-3936. Leukemia 17: 2257-2317.
17. Hoque MO, Kim MS, Ostrow KL, Liu J, Wisman GB, et al. (2008) Genome-wide promoter analysis uncovers portions of the cancer methylome. Cancer Res 68: 2661-2670.
18. Kim MS, Yamashita K, Baek JH, Park HL, Carvalho AL, et al. (2006) N-methyl-D-aspartate receptor type 2B is epigenetically inactivated and exhibits tumor-suppressive activity in human esophageal cancer. Cancer Res 66: 3409-3418.
19. Livak KJ, Schmittgen TD, (2001) Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) Method. Methods 25: 402-408.
20. Makarla PB, Saboorian MH, Ashfaq R, Toyooka KO, Toyooka S, et al. (2005) Promoter hypermethylation profile of ovarian epithelial neoplasms. Clin Cancer Res 11: 5365-5369.
21. Teodoridis JM, Hall J, Marsh S, Kannall HD, Smyth C, et al. (2005) CpG island methylation of DNA damage response genes in advanced ovarian cancer. Cancer Res 65: 8961-8967.
22. Wiley A, Katsaros D, Chen H, Rigault de la Longrais IA, Beeghly A, et al. (2006) Aberrant promoter methylation of multiple genes in malignant ovarian tumors and in ovarian tumors with low malignant potential. Cancer 107: 299-308.
23. Rathi A, Virmani AK, Schorge JO, Elias KJ, Maruyama R, et al. (2002) Methylation profiles of sporadic ovarian tumors and nonmalignant ovaries from high-risk women. Clin Cancer Res 8: 3324-3331.
24. Strathdee G, Appleton K, Illand M, Millan DW, Sargent J, et al. (2001) Primary ovarian carcinomas display multiple methylator phenotypes involving known tumor suppressor genes. Am J Pathol 158: 1121-1127.
25. Tam KF, Liu VW, Liu SS, Tsang PC, Cheung AN, et al. (2007) Methylation profile in benign, borderline and malignant ovarian tumors. J Cancer Res Clin Oncol 133: 331-341.
26. Tokumaru Y, Yamashita K, Kim MS, Park HL, Osada M, et al. (2008) The role of PGP9.5 as a tumor suppressor gene in human cancer. Int J Cancer 123: 753-759.
27. Liu JW, Nagpal JK, Sun W, Lee J, Kim MS, et al. (2008) ssDNA-binding protein 2 is frequently hypermethylated and suppresses cell growth in human prostate cancer. Clin Cancer Res 14: 3754-3760.
28. Brait M, Begum S, Carvalho AL, Dasgupta S, Vettore AL, et al. (2008) Aberrant promoter methylation of multiple genes during pathogenesis of bladder cancer. Cancer Epidemiol Biomarkers Prev 17: 2786-2794.
29. Wegiel B, Bjartell A, Tuomela J, Dizeyi N, Tinzl M, et al. (2008) Multiple cellular mechanisms related to cyclin A1 in prostate cancer invasion and metastasis. J Natl Cancer Inst 100: 1022-1036.
30. Rosenbaum E, Begum S, Brait M, Zahurak M, Maldonado L, et al. (2012) AIM1 promoter hypermethylation as a predictor of decreased risk of recurrence following radical prostatectomy. Prostate 72: 1133-1139.
31. Brait M, Maldonado L, Begum S, Loyo M, Wehle D, et al. (2012) DNA methylation profiles delineate epigenetic heterogeneity in seminoma and non-seminoma. Br J Cancer 106: 414-423.
32. Bittencourt Rosas SL, Caballero OL, Dong SM, da Costa Carvalho Mda G, Sidransky D, et al. (2001) Methylation status in the promoter region of the human PGP9.5 gene in cancer and normal tissues. Cancer Lett 170: 73-79.
33. Yamashita K, Park HL, Kim MS, Osada M, Tokumaru Y, et al. (2006) PGP9.5 methylation in diffuse-type gastric cancer. Cancer Res 66: 3921-3927.
34. Loyo M, Brait M, Kim MS, Ostrow KL, Jie CC, et al. (2011) A survey of methylated candidate tumor suppressor genes in nasopharyngeal carcinoma. Int J Cancer 128: 1393-1403.
35. Mizukami H, Shirahata A, Goto T, Sakata M, Saito M, et al. (2008) PGP9.5 methylation as a marker for metastatic colorectal cancer. Anticancer Res 28: 2697-2700.
36. Mastoraki A, Ioannidis E, Patsouris E, Safioleas M, Aroni K, (2009) PGP 9.5 expression in cutaneous keratoacanthomas and squamous cell carcinomas. Arch Dermatol Res 301: 653-658.
37. Okochi-Takada E, Nakazawa K, Wakabayashi M, Mori A, Ichimura S, et al. (2006) Silencing of the UCHL1 gene in human colorectal and ovarian cancers. Int J Cancer 119: 1338-1344.
38. Ostrow KL, Park HL, Hoque MO, Kim MS, Liu J, et al. (2009) Pharmacologic unmasking of epigenetically silenced genes in breast cancer. Clin Cancer Res 15: 1184-1191.
39. Bartolomucci A, Possenti R, Levi A, Pavone F, Moles A, (2007) The role of the vgf gene and VGF-derived peptides in nutrition and metabolism. Genes Nutr 2: 169-180.
40. Ruetschi U, Zetterberg H, Podust VN, Gottfries J, Li S, et al. (2005) Identification of CSF biomarkers for frontotemporal dementia using SELDI-TOF. Exp Neurol 196: 273-281.
41. Hahm S, Mizuno TM, Wu TJ, Wisor JP, Priest CA, et al. (1999) Targeted deletion of the Vgf gene indicates that the encoded secretory peptide precursor plays a novel role in the regulation of energy balance. Neuron 23: 537-548.
42. Esteller M, Garcia-Foncillas J, Andion E, Goodman SN, Hidalgo OF, et al. (2000) Inactivation of the DNA-repair gene MGMT and the clinical response of gliomas to alkylating agents. N Engl J Med 343: 1350-1354.
43. Akhoondi S, Lindstrom L, Widschwendter M, Corcoran M, Bergh J, et al. (2010) Inactivation of FBXW7/hCDC4-beta expression by promoter hypermethylation is associated with favorable prognosis in primary breast cancer. Breast Cancer Res 12: R105.
44. Wiley A, Katsaros D, Fracchioli S, Yu H, (2006) Methylation of the insulin-like growth factor binding protein-3 gene and prognosis of epithelial ovarian cancer. Int J Gynecol Cancer 16: 210-218.
45. Liu L, Tommasi S, Lee DH, Dammann R, Pfeifer GP, (2003) Control of microtubule stability by the RASSF1A tumor suppressor. Oncogene 22: 8125-8136.
46. Brown R, Hirst GL, Gallagher WM, McIlwrath AJ, Margison GP, et al. (1997) hMLH1 expression and cellular responses of ovarian tumour cells to treatment with cytotoxic anticancer agents. Oncogene 15: 45-52.
47. Ozdemir F, Altinisik J, Karateke A, Coksuer H, Buyru N, (2012) Methylation of tumor suppressor genes in ovarian cancer. Exp Ther Med 4: 1092-1096.
48. Fiegl H, Windbichler G, Mueller-Holzner E, Goebel G, Lechner M, et al. (2008) HOXA11 DNA methylation - a novel prognostic biomarker in ovarian cancer. Int J Cancer 123: 725-729.
49. Su HY, Lai HC, Lin YW, Chou YC, Liu CY, et al. (2009) An epigenetic marker panel for screening and prognostic prediction of ovarian cancer. Int J Cancer 124: 387-393.
50. Pils D, Horak P, Vanhara P, Anees M, Petz M, et al. (2013) Methylation status of TUSC3 is a prognostic factor in ovarian cancer. Cancer 119: 946-954.
51. Dai W, Teodoridis JM, Zeller C, Graham J, Hersey J, et al. (2011) Systematic CpG islands methylation profiling of genes in the wnt pathway in epithelial ovarian cancer identifies biomarkers of progression-free survival. Clin Cancer Res 17: 4052-4062.
52. Zeller C, Dai W, Curry E, Siddiq A, Walley A, et al. (2013) The DNA methylomes of serous borderline tumors reveal subgroups with malignant- or benign-like profiles. Am J Pathol 182: 668-677.
53. Maldonado L, Hoque MO, (2010) Epigenomics and ovarian carcinoma. Biomark Med 4: 543-570.